# Drug Discovery Hypothesis Generation: Multi-Agent System

## Executive Summary

This document describes a multi-agent system designed to generate novel, testable hypotheses for drug discovery. The architecture is informed by real-world drug discovery reasoning patterns observed in scientific literature (e.g., PLK1 kinase inhibitor research) and addresses the unique requirements of pharmaceutical hypothesis generation.

---

## 1. System Architecture Overview

### 1.1 Design Philosophy

Drug discovery hypothesis generation differs from general scientific reasoning in several key ways:

1. **Target-centric thinking**: Hypotheses revolve around molecular targets with specific structural and functional properties
2. **Druggability constraints**: Not all biological insights translate to therapeutic opportunities
3. **Novelty is paramount**: Redundant hypotheses waste significant R&D resources
4. **Iterative refinement**: Hypotheses evolve based on evidence quality and feasibility assessments

### 1.2 Agent Architecture

```
┌─────────────────────────────────────────────────────────────────────────────┐
│                        DRUG DISCOVERY HYPOTHESIS SYSTEM                      │
├─────────────────────────────────────────────────────────────────────────────┤
│                                                                              │
│  ┌──────────────┐    ┌──────────────┐    ┌──────────────┐                   │
│  │   TARGET     │───▶│  LITERATURE  │───▶│ DRUGGABILITY │                   │
│  │  HYPOTHESIS  │    │   EVIDENCE   │    │  ASSESSMENT  │                   │
│  │    AGENT     │    │    AGENT     │    │    AGENT     │                   │
│  └──────────────┘    └──────────────┘    └──────────────┘                   │
│         ▲                                       │                            │
│         │                                       ▼                            │
│         │                              ┌──────────────┐                      │
│         │                              │   NOVELTY    │                      │
│         │                              │     GAP      │                      │
│         │                              │    AGENT     │                      │
│         │                              └──────────────┘                      │
│         │                                       │                            │
│         │            ┌──────────────┐           ▼                            │
│         │            │  CONTROLLER  │◀──────────┤                            │
│         │            │    AGENT     │           │                            │
│         │            └──────────────┘           │                            │
│         │                   │                   ▼                            │
│         │                   │          ┌──────────────┐                      │
│         └───────────────────┼─────────▶│  PRECLINICAL │───▶ OUTPUT          │
│              (re-scope)     │          │    DESIGN    │                      │
│                             │          │    AGENT     │                      │
│                             │          └──────────────┘                      │
│                             │                   ▲                            │
│                             └───────────────────┘                            │
│                              (redesign experiment)                           │
│                                                                              │
└─────────────────────────────────────────────────────────────────────────────┘
```

---

## 2. Agent Definitions

### 2.1 Target Hypothesis Agent

**Role**: Transform research questions into structured, target-specific drug discovery hypotheses.

**Why this agent?**: Drug discovery begins with target identification. Unlike general scientific hypotheses, drug discovery hypotheses must specify:
- The molecular target (protein, pathway, etc.)
- The proposed intervention mechanism
- The expected therapeutic outcome
- The disease context

#### Detailed Instructions

```
SYSTEM PROMPT:

You are a senior drug discovery scientist specializing in target identification 
and hypothesis formulation.

TASK:
Convert the research question into a STRUCTURED drug discovery hypothesis.

REQUIRED COMPONENTS:
1. TARGET: Identify the specific molecular target (protein, receptor, enzyme, etc.)
2. MECHANISM: Specify the proposed mechanism of intervention
   - Inhibition (competitive, non-competitive, allosteric)
   - Activation/Agonism
   - Degradation (PROTACs, molecular glue)
   - Stabilization
   - Modulation of protein-protein interactions
3. DISEASE CONTEXT: Specify the therapeutic area and indication
4. RATIONALE: Brief biological rationale linking target to disease
5. MEASURABLE OUTCOME: What would validate this hypothesis?

OUTPUT FORMAT:
TARGET: [specific molecular target]
MECHANISM: [intervention type and specifics]
DISEASE: [therapeutic area and specific indication]
RATIONALE: [2-3 sentences on biological basis]
OUTCOME: [measurable validation criteria]
HYPOTHESIS_TYPE: [target_validation | mechanism_of_action | therapeutic_application]

CONSTRAINTS:
- Be specific about the target (e.g., "PLK1 polo-box domain" not just "PLK1")
- Avoid vague mechanisms (e.g., "modulates" without specifics)
- Ensure the outcome is experimentally testable
- If the question is too broad, focus on the most tractable angle

Do NOT:
- Generate multiple hypotheses (pick the strongest one)
- Include extensive background (that's for the evidence agent)
- Assess feasibility (that's for downstream agents)
```

#### Input/Output Specification

| Input | Output |
|-------|--------|
| `question`: str - Research question or therapeutic area of interest | `target`: str - Molecular target |
| `previous_hypothesis`: str (optional) - For refinement cycles | `mechanism`: str - Intervention mechanism |
| | `disease`: str - Therapeutic context |
| | `rationale`: str - Biological basis |
| | `outcome`: str - Validation criteria |
| | `hypothesis_type`: str - Classification |

---

### 2.2 Literature Evidence Agent

**Role**: Retrieve and synthesize existing scientific evidence relevant to the hypothesis.

**Why this agent?**: Evidence grounding prevents:
- Proposing already-disproven hypotheses
- Missing critical known mechanisms
- Overlooking existing drugs (competitive landscape)
- Ignoring known safety signals

#### Detailed Instructions

```
SYSTEM PROMPT:

You are a biomedical literature expert with deep knowledge of drug discovery.

TASK:
Synthesize known scientific evidence relevant to the drug discovery hypothesis.

RETRIEVE AND SUMMARIZE:

1. TARGET BIOLOGY
   - Known functions of the target
   - Expression patterns (tissue, disease-specific)
   - Knockout/knockdown phenotypes
   - Key interaction partners

2. DISEASE ASSOCIATION
   - Genetic evidence (GWAS, Mendelian genetics)
   - Expression changes in disease
   - Causal vs. correlative evidence
   - Patient stratification markers

3. EXISTING INTERVENTIONS
   - Known drugs/compounds targeting this target
   - Clinical trial history (successes and failures)
   - Resistance mechanisms observed
   - Safety signals from existing compounds

4. MECHANISM EVIDENCE
   - Evidence supporting proposed mechanism
   - Evidence against or complicating factors
   - Alternative mechanisms considered

5. KEY UNCERTAINTIES
   - What is NOT known that matters?
   - Conflicting evidence in the literature

OUTPUT FORMAT:
TARGET_BIOLOGY:
[summary]

DISEASE_ASSOCIATION:
[summary with strength of evidence: strong/moderate/weak/speculative]

EXISTING_INTERVENTIONS:
[summary of competitive landscape]

MECHANISM_EVIDENCE:
[supporting and conflicting evidence]

KEY_UNCERTAINTIES:
[critical knowledge gaps]

EVIDENCE_CONFIDENCE: [0.0-1.0]
CONFIDENCE_RATIONALE: [brief explanation of score]

CONSTRAINTS:
- Do NOT invent citations or data
- Clearly distinguish strong evidence from speculation
- Flag if critical information is missing
- Be explicit about the strength of genetic evidence (gold standard in drug discovery)
```

#### Input/Output Specification

| Input | Output |
|-------|--------|
| `hypothesis`: dict - Structured hypothesis from Target Hypothesis Agent | `target_biology`: str |
| | `disease_association`: str |
| | `existing_interventions`: str |
| | `mechanism_evidence`: str |
| | `key_uncertainties`: str |
| | `evidence_confidence`: float (0-1) |
| | `confidence_rationale`: str |

---

### 2.3 Druggability Assessment Agent

**Role**: Evaluate whether the target and proposed mechanism are amenable to drug intervention.

**Why this agent?**: This is the critical gap in generic hypothesis systems. Many biologically valid targets fail as drug targets due to:
- Lack of suitable binding pockets
- Selectivity challenges (off-target toxicity risk)
- Resistance mechanisms
- Tissue penetration requirements

#### Detailed Instructions

```
SYSTEM PROMPT:

You are a medicinal chemistry and structural biology expert specializing in 
druggability assessment.

TASK:
Evaluate the druggability of the proposed target and mechanism.

ASSESS THE FOLLOWING:

1. STRUCTURAL DRUGGABILITY
   - Is the target structure known? (X-ray, cryo-EM, AlphaFold)
   - Are there defined binding pockets?
   - Pocket characteristics (size, hydrophobicity, flexibility)
   - For PPI targets: interface characteristics
   - For allosteric mechanisms: known allosteric sites?

2. SELECTIVITY LANDSCAPE
   - How similar is this target to related family members?
   - What are the key selectivity determinants?
   - Risk of off-target effects (list specific concerns)
   - Therapeutic window considerations

3. MODALITY SUITABILITY
   - Small molecule feasibility
   - Biologic feasibility (antibody, peptide)
   - Emerging modalities (PROTAC, ASO, siRNA, gene therapy)
   - Recommended modality with rationale

4. RESISTANCE RISK
   - Known resistance mutations (from existing drugs)
   - Predicted resistance mechanisms
   - Strategies to mitigate resistance

5. DELIVERY CONSIDERATIONS
   - Target localization (intracellular, membrane, extracellular)
   - Tissue distribution requirements
   - Blood-brain barrier considerations (if CNS)
   - Oral bioavailability feasibility

OUTPUT FORMAT:
STRUCTURAL_DRUGGABILITY:
[assessment]
SCORE: [0.0-1.0]

SELECTIVITY_ASSESSMENT:
[assessment]
KEY_RISKS: [list specific off-target concerns]

RECOMMENDED_MODALITY: [small molecule | biologic | PROTAC | ASO | other]
MODALITY_RATIONALE: [why this modality]

RESISTANCE_RISK:
[assessment]
MITIGATION_STRATEGIES: [if applicable]

DELIVERY_CONSIDERATIONS:
[assessment]

OVERALL_DRUGGABILITY_SCORE: [0.0-1.0]
DRUGGABILITY_RATIONALE: [key factors driving the score]

CRITICAL_CONCERNS: [list any deal-breakers or major red flags]
```

#### Input/Output Specification

| Input | Output |
|-------|--------|
| `hypothesis`: dict - Structured hypothesis | `structural_druggability`: str + score |
| `evidence`: dict - From Literature Evidence Agent | `selectivity_assessment`: str + risks |
| | `recommended_modality`: str + rationale |
| | `resistance_risk`: str + mitigations |
| | `delivery_considerations`: str |
| | `druggability_score`: float (0-1) |
| | `critical_concerns`: list[str] |

---

### 2.4 Novelty Gap Agent

**Role**: Assess the novelty of the hypothesis and identify underexplored opportunities.

**Why this agent?**: This is the KEY DIFFERENTIATOR for drug discovery. The PLK1 example illustrates this perfectly:
- ATP-competitive PLK1 inhibitors: heavily explored, selectivity issues
- PBD-targeting inhibitors: underexplored, potentially more selective
- The "gap" (PBD targeting) is where the novel hypothesis lies

#### Detailed Instructions

```
SYSTEM PROMPT:

You are a drug discovery strategist specializing in competitive intelligence 
and white space analysis.

TASK:
Assess the novelty of the hypothesis and identify the key innovation angle.

EVALUATE:

1. COMPETITIVE LANDSCAPE
   - How many programs are pursuing this target?
   - What mechanisms have been tried?
   - Current clinical stage of most advanced programs
   - Recent failures and their reasons

2. NOVELTY ASSESSMENT
   Classify the hypothesis novelty:
   - FIRST_IN_CLASS: Novel target, no prior drug discovery efforts
   - BEST_IN_CLASS: Known target, differentiated mechanism or properties
   - ME_TOO: Known target, similar mechanism to existing efforts
   - FAST_FOLLOWER: Recent target validation, early competitive entry

3. DIFFERENTIATION ANALYSIS
   - What makes this hypothesis different from existing approaches?
   - Is the differentiation scientifically meaningful?
   - Is the differentiation clinically meaningful?

4. WHITE SPACE IDENTIFICATION
   - What aspects of this target/mechanism are underexplored?
   - Why might they be underexplored? (technical barriers, dogma, oversight)
   - What would unlock the white space?

5. FREEDOM TO OPERATE (HIGH LEVEL)
   - Are there dominant patent positions?
   - Is the space crowded with IP?
   - Potential for differentiated IP position

OUTPUT FORMAT:
COMPETITIVE_LANDSCAPE:
[summary of existing efforts]
PROGRAMS_COUNT: [approximate number]
MOST_ADVANCED_STAGE: [preclinical | phase1 | phase2 | phase3 | approved]

NOVELTY_CLASSIFICATION: [FIRST_IN_CLASS | BEST_IN_CLASS | ME_TOO | FAST_FOLLOWER]
NOVELTY_RATIONALE: [why this classification]

DIFFERENTIATION:
[what makes this different]
SCIENTIFIC_DIFFERENTIATION: [strong | moderate | weak | none]
CLINICAL_DIFFERENTIATION: [strong | moderate | weak | none]

WHITE_SPACE_OPPORTUNITIES:
[underexplored angles]

FREEDOM_TO_OPERATE: [favorable | challenging | highly_constrained]

NOVELTY_SCORE: [0.0-1.0]
RECOMMENDATION: [proceed | refine_for_differentiation | pivot | abandon]
```

#### Input/Output Specification

| Input | Output |
|-------|--------|
| `hypothesis`: dict | `competitive_landscape`: str |
| `evidence`: dict | `novelty_classification`: str |
| `druggability`: dict | `differentiation`: str + scores |
| | `white_space`: str |
| | `freedom_to_operate`: str |
| | `novelty_score`: float (0-1) |
| | `recommendation`: str |

---

### 2.5 Preclinical Design Agent

**Role**: Design a minimal experimental plan to test the hypothesis.

**Why this agent?**: A hypothesis is only valuable if it's testable. This agent ensures:
- Experiments are feasible and appropriately scoped
- The right models and assays are proposed
- Success criteria are defined upfront

#### Detailed Instructions

```
SYSTEM PROMPT:

You are a preclinical drug discovery scientist with expertise in experimental 
design and translational research.

TASK:
Design a minimal but rigorous experimental plan to test the hypothesis.

DESIGN THE FOLLOWING:

1. TARGET VALIDATION EXPERIMENTS
   - Genetic validation (siRNA, CRISPR, knockout)
   - Tool compound validation (if available)
   - Recommended cell lines/models
   - Key readouts and endpoints

2. MECHANISM OF ACTION STUDIES
   - Biochemical assays (binding, enzymatic activity)
   - Cellular assays (target engagement, pathway modulation)
   - Biomarkers of target engagement

3. EFFICACY MODELS
   - In vitro efficacy models
   - In vivo efficacy models (if warranted)
   - Translational biomarkers

4. SAFETY CONSIDERATIONS
   - Key safety studies needed
   - Anticipated liabilities based on target biology
   - Selectivity panel recommendations

5. GO/NO-GO CRITERIA
   - Define clear success criteria for each stage
   - Define failure criteria (what would kill the hypothesis)
   - Timeline estimates

OUTPUT FORMAT:
TARGET_VALIDATION:
  EXPERIMENTS: [list]
  MODELS: [cell lines, organisms]
  READOUTS: [endpoints]
  TIMELINE: [estimate]
  GO_CRITERIA: [success threshold]
  NO_GO_CRITERIA: [failure threshold]

MECHANISM_STUDIES:
  BIOCHEMICAL: [assays]
  CELLULAR: [assays]
  BIOMARKERS: [list]

EFFICACY_MODELS:
  IN_VITRO: [models and endpoints]
  IN_VIVO: [models if needed, with justification]
  TRANSLATIONAL_BIOMARKERS: [list]

SAFETY_STUDIES:
  ANTICIPATED_LIABILITIES: [based on target biology]
  RECOMMENDED_PANELS: [selectivity, toxicity]

CRITICAL_PATH:
[sequence of experiments with decision points]

FEASIBILITY_SCORE: [0.0-1.0]
FEASIBILITY_RATIONALE: [key factors]

RESOURCE_ESTIMATE:
  TIMELINE: [months]
  COMPLEXITY: [low | medium | high]
```

#### Input/Output Specification

| Input | Output |
|-------|--------|
| `hypothesis`: dict | `target_validation`: dict |
| `evidence`: dict | `mechanism_studies`: dict |
| `druggability`: dict | `efficacy_models`: dict |
| `novelty`: dict | `safety_studies`: dict |
| | `critical_path`: str |
| | `feasibility_score`: float (0-1) |
| | `resource_estimate`: dict |

---

### 2.6 Controller Agent

**Role**: Orchestrate the workflow and make routing decisions based on agent outputs.

**Why this agent?**: Drug discovery is inherently iterative. The controller enables:
- Dynamic re-routing based on quality scores
- Hypothesis refinement when needed
- Early termination of non-viable hypotheses
- Final go/no-go decisions

#### Detailed Instructions

```
SYSTEM PROMPT:

You are a drug discovery portfolio manager responsible for go/no-go decisions.

TASK:
Based on the outputs from all agents, decide the next action.

DECISION LOGIC:

1. ITERATION LIMIT CHECK
   - If iterations >= 5: Force terminal decision (GO or NO_GO)

2. EVIDENCE QUALITY CHECK
   - If evidence_confidence < 0.4: Route to LITERATURE_EVIDENCE (retrieve more)
   - Rationale: Insufficient evidence to make informed decisions

3. DRUGGABILITY CHECK
   - If druggability_score < 0.3: Route to TARGET_HYPOTHESIS (re-scope)
   - Rationale: Target is not druggable, need different angle
   - If druggability_score 0.3-0.5 AND critical_concerns exist: 
     Route to TARGET_HYPOTHESIS with specific feedback

4. NOVELTY CHECK
   - If novelty_score < 0.3: Route to TARGET_HYPOTHESIS (re-scope for differentiation)
   - If novelty_recommendation == "pivot": Route to TARGET_HYPOTHESIS
   - Rationale: Hypothesis lacks differentiation, needs refinement

5. FEASIBILITY CHECK
   - If feasibility_score < 0.4: Route to PRECLINICAL_DESIGN (redesign)
   - Rationale: Experimental plan is not feasible

6. TERMINAL DECISIONS
   - If all scores >= 0.5 AND no critical concerns: GO
   - If iterations >= 5 AND any score < 0.3: NO_GO
   - If critical deal-breakers identified: NO_GO with rationale

OUTPUT:
ACTION: [re_scope | retrieve_more | redesign_experiment | GO | NO_GO]
RATIONALE: [explanation for decision]
FEEDBACK: [specific guidance for the target agent if re-routing]
CONFIDENCE: [confidence in this decision]
```

---

## 3. Information Flow

### 3.1 State Schema

```python
class DrugDiscoveryState(TypedDict, total=False):
    # Input
    question: str
    
    # Target Hypothesis Agent outputs
    target: str
    mechanism: str
    disease: str
    rationale: str
    outcome: str
    hypothesis_type: str
    
    # Literature Evidence Agent outputs
    target_biology: str
    disease_association: str
    existing_interventions: str
    mechanism_evidence: str
    key_uncertainties: str
    evidence_confidence: float
    
    # Druggability Assessment Agent outputs
    structural_druggability: str
    selectivity_assessment: str
    recommended_modality: str
    resistance_risk: str
    delivery_considerations: str
    druggability_score: float
    critical_concerns: List[str]
    
    # Novelty Gap Agent outputs
    competitive_landscape: str
    novelty_classification: str
    differentiation: str
    white_space: str
    novelty_score: float
    novelty_recommendation: str
    
    # Preclinical Design Agent outputs
    target_validation: str
    mechanism_studies: str
    efficacy_models: str
    safety_studies: str
    critical_path: str
    feasibility_score: float
    resource_estimate: str
    
    # Controller outputs
    controller_action: str
    controller_rationale: str
    controller_feedback: str
    
    # Metadata
    iteration: int
    decision_history: List[Dict]
```

### 3.2 Context Sharing Strategy

Each agent receives CUMULATIVE context from all previous agents:

```
┌─────────────────────────────────────────────────────────────────┐
│                     CONTEXT ACCUMULATION                        │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  Agent 1 (Target Hypothesis)                                    │
│    Input:  question                                             │
│    Output: hypothesis                                           │
│                                                                 │
│  Agent 2 (Literature Evidence)                                  │
│    Input:  question + hypothesis                                │
│    Output: evidence                                             │
│                                                                 │
│  Agent 3 (Druggability)                                         │
│    Input:  question + hypothesis + evidence                     │
│    Output: druggability                                         │
│                                                                 │
│  Agent 4 (Novelty)                                              │
│    Input:  question + hypothesis + evidence + druggability      │
│    Output: novelty                                              │
│                                                                 │
│  Agent 5 (Preclinical Design)                                   │
│    Input:  question + hypothesis + evidence + druggability      │
│            + novelty                                            │
│    Output: experimental_plan                                    │
│                                                                 │
│  Agent 6 (Controller)                                           │
│    Input:  ALL accumulated state                                │
│    Output: routing_decision                                     │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

**Rationale for Cumulative Context**:
- Downstream agents need upstream context for coherent reasoning
- Druggability assessment needs to know the specific mechanism proposed
- Novelty assessment needs to know what existing interventions were found
- Preclinical design needs all context to propose appropriate experiments

---

## 4. Routing Strategy: Dynamic Routing

### 4.1 Why Dynamic Routing?

**Sequential routing** (each agent runs once in fixed order) is insufficient for drug discovery because:

1. **Iterative Nature**: Real drug discovery involves cycles of hypothesis refinement
2. **Quality Gates**: Poor scores at any stage should trigger re-evaluation
3. **Early Termination**: Non-viable hypotheses should be killed early
4. **Feedback Loops**: Downstream insights should inform upstream refinement

**Dynamic routing** enables:
- Re-scoping hypotheses that fail druggability or novelty checks
- Retrieving more evidence when confidence is low
- Redesigning experiments when feasibility is poor
- Making informed go/no-go decisions

### 4.2 Routing Rules

```
┌─────────────────────────────────────────────────────────────────┐
│                      ROUTING DECISION TREE                      │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  After Controller evaluates all scores:                         │
│                                                                 │
│  IF iteration >= 5:                                             │
│      → Terminal decision (GO or NO_GO based on scores)          │
│                                                                 │
│  ELSE IF evidence_confidence < 0.4:                             │
│      → Route to LITERATURE_EVIDENCE                             │
│      → Feedback: "Retrieve more evidence on [specific gap]"     │
│                                                                 │
│  ELSE IF druggability_score < 0.3:                              │
│      → Route to TARGET_HYPOTHESIS                               │
│      → Feedback: "Re-scope: [druggability concern]"             │
│                                                                 │
│  ELSE IF novelty_score < 0.3:                                   │
│      → Route to TARGET_HYPOTHESIS                               │
│      → Feedback: "Differentiate: [competitive concern]"         │
│                                                                 │
│  ELSE IF feasibility_score < 0.4:                               │
│      → Route to PRECLINICAL_DESIGN                              │
│      → Feedback: "Redesign: [feasibility concern]"              │
│                                                                 │
│  ELSE IF all_scores >= 0.5 AND no_critical_concerns:            │
│      → GO                                                       │
│                                                                 │
│  ELSE:                                                          │
│      → NO_GO with rationale                                     │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### 4.3 Feedback Propagation

When re-routing, the controller provides SPECIFIC FEEDBACK:

```python
# Example: Re-scoping due to poor druggability
{
    "action": "re_scope",
    "target_agent": "target_hypothesis",
    "feedback": {
        "reason": "ATP-binding site is highly conserved across PLK family",
        "suggestion": "Consider targeting the polo-box domain instead",
        "constraint": "Must achieve >100x selectivity over PLK2/3"
    }
}
```

This feedback is injected into the Target Hypothesis Agent's next invocation.

---

## 5. LangGraph Implementation

### 5.1 Node Definitions

```python
# Nodes correspond to agents
nodes = {
    "target_hypothesis": target_hypothesis_agent,
    "literature_evidence": literature_evidence_agent,
    "druggability": druggability_agent,
    "novelty": novelty_agent,
    "preclinical_design": preclinical_design_agent,
    "controller": controller_agent
}
```

### 5.2 Edge Definitions

```python
# Sequential edges (forward flow)
edges = [
    ("target_hypothesis", "literature_evidence"),
    ("literature_evidence", "druggability"),
    ("druggability", "novelty"),
    ("novelty", "preclinical_design"),
    ("preclinical_design", "controller")
]

# Conditional edges (dynamic routing from controller)
conditional_edges = {
    "controller": {
        "re_scope": "target_hypothesis",
        "retrieve_more": "literature_evidence",
        "redesign": "preclinical_design",
        "GO": END,
        "NO_GO": END
    }
}
```

### 5.3 Graph Visualization

```
                    ┌─────────────────┐
                    │  START (Entry)  │
                    └────────┬────────┘
                             │
                             ▼
                    ┌─────────────────┐
        ┌──────────│    TARGET       │◀─────────────┐
        │          │   HYPOTHESIS    │              │
        │          └────────┬────────┘              │
        │                   │                       │
        │                   ▼                       │
        │          ┌─────────────────┐              │
        │    ┌────▶│   LITERATURE    │              │
        │    │     │    EVIDENCE     │              │
        │    │     └────────┬────────┘              │
        │    │              │                       │
        │    │              ▼                       │
        │    │     ┌─────────────────┐              │
        │    │     │  DRUGGABILITY   │              │
        │    │     │   ASSESSMENT    │              │
        │    │     └────────┬────────┘              │
        │    │              │                       │
        │    │              ▼                       │
        │    │     ┌─────────────────┐              │
        │    │     │    NOVELTY      │              │
        │    │     │      GAP        │              │
        │    │     └────────┬────────┘              │
        │    │              │                       │
        │    │              ▼                       │
        │    │     ┌─────────────────┐              │
        │    └─────│   PRECLINICAL   │◀────────┐    │
        │          │     DESIGN      │         │    │
        │          └────────┬────────┘         │    │
        │                   │                  │    │
        │                   ▼                  │    │
        │          ┌─────────────────┐         │    │
        │          │   CONTROLLER    │─────────┴────┘
        │          └────────┬────────┘    (re-route)
        │                   │
        │         ┌─────────┴─────────┐
        │         ▼                   ▼
        │   ┌──────────┐        ┌──────────┐
        │   │    GO    │        │  NO_GO   │
        │   │ (success)│        │ (reject) │
        │   └──────────┘        └──────────┘
        │
        └──── (re_scope feedback loop)
```

---

## 6. Decision Rationale Summary

### 6.1 Why These Specific Agents?

| Agent | Rationale |
|-------|-----------|
| Target Hypothesis | Drug discovery is target-centric; need structured hypothesis format |
| Literature Evidence | Evidence grounding prevents redundant/disproven hypotheses |
| Druggability | **Critical gap** in generic systems; many valid targets aren't druggable |
| Novelty | **Key differentiator**; drug discovery requires novel angles |
| Preclinical Design | Hypothesis value depends on testability |
| Controller | Enables iterative refinement characteristic of real drug discovery |

### 6.2 Why Dynamic vs Sequential Routing?

| Aspect | Sequential | Dynamic (Chosen) |
|--------|------------|------------------|
| Reflects real drug discovery? | No | Yes |
| Handles poor-quality intermediate outputs? | No | Yes |
| Enables hypothesis refinement? | No | Yes |
| Allows early termination? | No | Yes |
| Complexity | Lower | Higher |
| Token usage | Predictable | Variable |

**Conclusion**: Dynamic routing better models real drug discovery reasoning despite higher complexity.

### 6.3 Why These Routing Thresholds?

| Threshold | Value | Rationale |
|-----------|-------|-----------|
| Evidence confidence | < 0.4 | Below this, decisions are speculative |
| Druggability score | < 0.3 | Below this, target is likely undruggable |
| Novelty score | < 0.3 | Below this, hypothesis is likely redundant |
| Feasibility score | < 0.4 | Below this, experiments are impractical |
| Max iterations | 5 | Prevents infinite loops; forces decision |

---

## 7. Example Walkthrough

### Input
```
Question: "Can we develop a more selective PLK1 inhibitor for cancer treatment?"
```

### Iteration 1

**Target Hypothesis Agent**:
```
TARGET: PLK1 kinase domain ATP-binding site
MECHANISM: ATP-competitive inhibition
DISEASE: Solid tumors with PLK1 overexpression
RATIONALE: PLK1 is overexpressed in many cancers and drives proliferation
OUTCOME: >90% PLK1 inhibition in tumor xenografts
```

**Literature Evidence Agent**:
```
EXISTING_INTERVENTIONS: Multiple ATP-competitive inhibitors (BI2536, Volasertib)
                        in clinical trials with selectivity issues
EVIDENCE_CONFIDENCE: 0.7
```

**Druggability Agent**:
```
SELECTIVITY_ASSESSMENT: ATP-binding site highly conserved across PLK family
                        High risk of PLK2/3 inhibition (toxicity concern)
DRUGGABILITY_SCORE: 0.4
CRITICAL_CONCERNS: ["Selectivity challenge in ATP pocket"]
```

**Novelty Agent**:
```
NOVELTY_CLASSIFICATION: ME_TOO
COMPETITIVE_LANDSCAPE: >10 clinical programs targeting ATP site
NOVELTY_SCORE: 0.2
RECOMMENDATION: pivot
```

**Controller Decision**:
```
ACTION: re_scope
RATIONALE: Low novelty (0.2) - hypothesis is not differentiated
FEEDBACK: "Consider targeting polo-box domain (PBD) instead of ATP site
           for improved selectivity. PBD is unique to PLK family."
```

### Iteration 2

**Target Hypothesis Agent** (with feedback):
```
TARGET: PLK1 polo-box domain (PBD)
MECHANISM: PBD inhibition disrupting substrate recognition
DISEASE: Solid tumors with PLK1 overexpression
RATIONALE: PBD is unique to PLK family, enabling selective inhibition
OUTCOME: Selective PLK1 inhibition with >100x selectivity over PLK2/3
```

**Literature Evidence Agent**:
```
EXISTING_INTERVENTIONS: Few PBD inhibitors (Poloxin, early stage)
EVIDENCE_CONFIDENCE: 0.6
KEY_UNCERTAINTIES: PBD inhibitor efficacy in vivo less validated
```

**Druggability Agent**:
```
STRUCTURAL_DRUGGABILITY: PBD structure known, defined binding pocket
SELECTIVITY_ASSESSMENT: PBD less conserved, selectivity achievable
DRUGGABILITY_SCORE: 0.6
```

**Novelty Agent**:
```
NOVELTY_CLASSIFICATION: BEST_IN_CLASS
WHITE_SPACE: PBD targeting underexplored despite structural rationale
NOVELTY_SCORE: 0.7
RECOMMENDATION: proceed
```

**Preclinical Design Agent**:
```
TARGET_VALIDATION: CRISPR PLK1 knockin with PBD mutations
MECHANISM_STUDIES: FP assay for PBD binding, cellular PLK1 localization
FEASIBILITY_SCORE: 0.7
```

**Controller Decision**:
```
ACTION: GO
RATIONALE: All scores >= 0.5, novel differentiation angle, feasible plan
```

---

## 8. Implementation Checklist

- [ ] Define State schema with all agent outputs
- [ ] Implement each agent with detailed prompts
- [ ] Configure LangGraph with nodes and edges
- [ ] Implement conditional routing from controller
- [ ] Add iteration counter and max iteration logic
- [ ] Implement feedback propagation for re-routing
- [ ] Add logging for decision history
- [ ] Test with diverse drug discovery questions
- [ ] Tune routing thresholds based on output quality

---

## 9. Future Enhancements

1. **Real Literature Integration**: Connect to PubMed, ChEMBL, ClinicalTrials.gov APIs
2. **Structure-Aware Reasoning**: Integrate AlphaFold/PDB for structural druggability
3. **Patent Landscape**: Add Freedom-to-Operate analysis with patent databases
4. **Multi-Hypothesis Generation**: Generate and compare multiple hypotheses
5. **Human-in-the-Loop**: Add checkpoints for expert review before terminal decisions

---

## Appendix: Prompt Templates

See the Python implementation file for complete prompt templates for each agent.
